A Phase 1b/2 trial of PCM-075 assessing safety in Acute-myeloid-leukaemia patients.

Trial Profile

A Phase 1b/2 trial of PCM-075 assessing safety in Acute-myeloid-leukaemia patients.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs PCM 075 (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jul 2017 According to a TrovaGene media release, Dr. Jorge Eduardo Cortes is the led investigator for this study
    • 27 Jul 2017 According to a TrovaGene media release, the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Phase 1b/2 Trial.
    • 06 Jul 2017 According to a TrovaGene media release, PRA Health Sciences, a contract research organization (CRO), will conduct this trial. PRA will assist the company in clinical site recruitment, clinical operations and regulatory proceedings for the development of PCM-075 in AML.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top